Purpose: We reviewed the outcomes in men treated with permanent prostate brachytherapy (PPB).
Material And Methods: A total of 1,449 consecutive patients with a mean age of 68 years treated with PPB between 1992 and 2000 and mean pretreatment prostate specific antigen (PSA) 10.1 ng/ml were included in this study. Of the patients 55% presented with Gleason 6 tumors and 28% had Gleason 7 disease. A total of 400 patients (27%) were treated with neoadjuvant hormones and 301 (20%) were treated in combination with external radiation plus PPB. Several biochemical freedom from recurrence (BFR) definitions were determined. Statistical analysis consisted of log rank testing, Kaplan-Meier estimates and Cox regression analysis.
Results: Median followup was 82 months with 39 patients at risk at for 144 months. Overall and disease specific survival at 12 years was 81% and 93%, respectively. The 12-year BFR was 81%, 78%, 74% and 77% according to the American Society for Therapeutic Radiology and Oncology (ASTRO), ASTRO-Kattan, ASTRO-Last Call and Houston definitions, respectively. The 12-year ASTRO-Kattan BFR using risk stratification was 89%, 78% and 63% in patients at low, intermediate and high risk, respectively (p = 0.0001). Multivariate analysis identified the dose that 90% of the target volume received (p <0.0001), pretreatment PSA (p = 0.001), Gleason score (p = 0.002), the percent positive core biopsies (p = 0.037), clinical stage (p = 0.689), the addition of hormones (p = 0.655) and the addition of external radiation (p = 0.724) for predicting BFR-ASTRO. Five-year disease specific survival was 44% in patients with a PSA doubling time of less than 12 months vs 88% in those with a PSA doubling time of 12 months or greater (p = 0.0001).
Conclusions: PPB offers acceptable 12-year BFR in patients who present with clinically localized prostate cancer. Implant dosimetry continues as an important predictor for BFR, while the addition of adjuvant therapies such as hormones and external radiation are insignificant. In patients who experience biochemical failure it appears that PSA doubling time is an important predictor of survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.juro.2008.03.133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy.
Brachytherapy
November 2024
Carleton Laboratory for Radiotherapy Physics, Physics Department, Carleton University, Ottawa, Ontario, Canada. Electronic address:
Purpose: Demonstrate quantitative characterization of 3D patient-specific absorbed dose distributions using Haralick texture analysis, and interpret measures in terms of underlying physics and radiation dosimetry.
Methods: Retrospective analysis is performed for 137 patients who underwent permanent implant prostate brachytherapy using two simulation conditions: "TG186" (realistic tissues including 0-3.8% intraprostatic calcifications; interseed attenuation) and "TG43" (water-model; no interseed attenuation).
Predictors of corporo-venocclusive dysfunction in men with bilateral nerve-sparing radical prostatectomy.
J Sex Med
January 2025
Sexual & Reproductive Medicine Program, Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
Article Synopsis
- Erectile dysfunction (ED) can occur in men who have had bilateral nerve-sparing surgery, with corporo-venocclusive dysfunction (CVOD) being a primary cause of permanent ED after radical prostatectomy (RP).
- A study examined comorbidity factors linked to CVOD in men without prior ED who underwent RP, finding significant associations with increased age and obstructive sleep apnea (OSA).
- The research highlights that comorbidities, particularly OSA, influence recovery of erectile function post-surgery; however, the findings may not apply broadly to all patients, as the study focused on men already seeking treatment for ED.
Current status of the working environment of brachytherapy in Japan: a nationwide survey-based analysis focusing on radiotherapy technologists and medical physicists.
J Radiat Res
December 2024
Department of Radiology, University of Yamanashi Faculty of Medicine, 1110 Shimokato, Chuo-shi, Yamanashi 409-3898, Japan.
Article Synopsis
- Brachytherapy (BT), particularly high dose rate (HDR) BT, has become more complex due to advanced techniques, necessitating significant training for radiotherapy technologists and medical physicists (RTMPs).
- A survey conducted across 837 radiation treatment facilities in Japan revealed varying working times for HDR procedures and low quality control (QC) implementation rates for BT compared to external beam radiation therapy (EBRT).
- The findings underscore a need for improved training and education for RTMPs to enhance the quality and safety of BT practices in Japan.
Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.
Curr Urol Rep
October 2024
Department of Urology, Northwell Health, Manhasset, NY, USA.
Purpose Of Review: The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.
Recent Findings: The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!